iRhythm Technologies Enters Into License Agreement with BioIntelliSense for Multiparameter Sensor Technology for Use in Ambulatory Cardiac Monitoring Page 1

iRhythm has been granted an exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending noninvasive blood pressure technologies for use within the ambulatory cardiac monitoring (ACM) market

SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict and prevent disease, today announced that the company has signed an exclusive license agreement with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to develop and commercialize certain proprietary technology assets within ambulatory cardiac monitoring (ACM).